DrugPatentWatch Database Preview
ALIQOPA Drug Profile
Which patents cover Aliqopa, and what generic alternatives are available?
Aliqopa is a drug marketed by Bayer Healthcare and is included in one NDA. There are three patents protecting this drug.
This drug has one hundred and forty-four patent family members in forty-nine countries.
The generic ingredient in ALIQOPA is copanlisib dihydrochloride. One supplier is listed for this compound. Additional details are available on the copanlisib dihydrochloride profile page.
Summary for ALIQOPA
| International Patents: | 144 |
| US Patents: | 3 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 1 |
| Clinical Trials: | 1 |
| Drug Prices: | Drug price information for ALIQOPA |
| Prior Art and Litigation Support | Order Prior Art and Litigation support for ALIQOPA |
| DailyMed Link: | ALIQOPA at DailyMed |
Generic Entry Opportunity Date for ALIQOPA
Generic Entry Date for ALIQOPA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
POWDER;IV (INFUSION) |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
US Patents and Regulatory Information for ALIQOPA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bayer Healthcare | ALIQOPA | copanlisib dihydrochloride | POWDER;INTRAVENOUS | 209936-001 | Sep 14, 2017 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
| Bayer Healthcare | ALIQOPA | copanlisib dihydrochloride | POWDER;INTRAVENOUS | 209936-001 | Sep 14, 2017 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
| Bayer Healthcare | ALIQOPA | copanlisib dihydrochloride | POWDER;INTRAVENOUS | 209936-001 | Sep 14, 2017 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | Y | Y | ➤ Try a Free Trial | ||
| Bayer Healthcare | ALIQOPA | copanlisib dihydrochloride | POWDER;INTRAVENOUS | 209936-001 | Sep 14, 2017 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | Y | Y | ➤ Try a Free Trial | ||
| Bayer Healthcare | ALIQOPA | copanlisib dihydrochloride | POWDER;INTRAVENOUS | 209936-001 | Sep 14, 2017 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
International Patents for ALIQOPA
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Ukraine | 96965 | ➤ Try a Free Trial |
| Brazil | PI0314830 | ➤ Try a Free Trial |
| Norway | 331457 | ➤ Try a Free Trial |
| South Korea | 101501785 | ➤ Try a Free Trial |
| European Patent Office | 2096919 | ➤ Try a Free Trial |
| Costa Rica | 20130511 | ➤ Try a Free Trial |
| Country | Patent Number | Estimated Expiration |
